## BACKGROUND. The number of elderly people with small cell lung carcinoma (SCLC) is increasing and currently nearly 25% are older than 70 years. Elderly patients may not tolerate intensive therapy and, therefore, often do not receive such treatment. Additionally, age may be an independent predicto
Small cell carcinoma of the lung. Treatment in the community
β Scribed by Charles H. Diggs; James E. Engeler Jr.; Edward J. Prendergast; Kristen Kramer
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 688 KB
- Volume
- 69
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Nine patients with βlimitedβ (thoracic) smallβcell lung carcinoma were treated with combined chemotherapy and radiotherapy (involved field and prophylactic whole brain). Induction drugs were Vincristine, Adriamycin, and Cyclophosphamide; and Cyclophosphamide, Vincristine, and CCNU for m
The COPP regimen (cyclophosphamide, Oncovin, procarbazine, prednisone) was one of the first chemotherapy programs to prolong survival in small cell lung cancer (SCLC) significantly. Results with this regimen in 50 patients with SCLC show an overall median survival of 10 months. Survival was decrease
## BACKGROUND. Small cell lung carcinoma (SC1.C) has been divided into three subtypes: pure SCLC. mixed small cellllarge cell carcinoma (mixed SCILC), and combined SCLC. Patients with mixed SC/LC show a worse prognosis than those with pure SCLC. ## METHODS. Persistence of histologic subtype in
## Abstract Small cell carcinoma of the lung is extremely sensitive to chemotherapy and radiation therapy. We describe the case of a patient who had a complete response to such treatment but relapsed with meningeal carcinomatosis. We propose that prophylactic therapy to the spinal cord as well as t